Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Obesity mechanisms in the clinic: which overlap, and which branch out

Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss

August 10, 2023 12:44 AM UTC
Updated on Aug 12, 2023 at 12:53 AM UTC

The success of obesity therapies targeting the incretin axis has galvanized a wave of drug development with different molecular targets but similar physiological mechanisms of action. A handful of clinical programs are going further afield, some of which could stand out by shrinking fat and not muscle.

At least 38 clinical programs are disclosed in company pipelines for obesity, with even more targeting indications where obesity is frequently part of disease presentation, such as diabetes, non-alcoholic steatohepatitis (NASH) or rare genetic disorders. More than half of the obesity programs mimic incretins — peptide hormones that stimulate decreases in blood glucose levels. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article